Dodger Fans Are Invited to Help Fight Cancer with the Return of Stella Abrera to Los Angeles

Dodger fans are known world wide for their passion for their boys in blue, but we also know that Dodger fans are passionate when it comes to helping those in need, as well.

At Dodgers Nation, we’re proud to be working with the Aveni Foundation to help support a night to Fight Cancer on November 14, 2019 with the return of Stella Abrera to Los Angeles.

Stella Abrera is the principal dancer for the American Ballet Theatre, which is known as one of the world’s greatest classical ballet companies and was recognized by Congress as “America’s National Ballet Company!” As the highest ranking ballerina in the ABT, Stella is coming home to where she began her dancing career out of Pasadena when she was 5 years old.

We were lucky enough to get a special message from her last week to encourage Dodger fans to come and support the event in Downtown Los Angeles:

View this post on Instagram

A post shared by Dodgers Nation (@dodgersnation)

We’ll be there and hope you can make it as well.

CLICK HERE TO BUY TICKETS 

LOCATION
Aratani Theatre
244  S San Pedro St.
Los Angeles, CA 90012

DATE
Thursday at 7pm
November 14, 2019

The Aveni Foundation is committed to expediting the development of gene-targeted therapies for metastatic cancers and other unmet medical needs.
Metastatic cancer is associated with an invariably fatal outcome accounting for 9.6 million deaths worldwide in 2018, a global burden which is expected to increase beyond 16 million by 2040 (World Health Organization, 2019; American Cancer Society, 2019). It is our mission to support the timely development of innovative targeted therapies for cancers and other diseases.

For our first program investment, Aveni Foundation is raising $10M for specific projects that aim to develop promising new therapies which provide clinical benefits without the toxic side effects of chemotherapy.

The foundation is named in honor of Fr. Joseph Aveni, RCJ, a Rogationist priest who experienced significant clinical benefit from a gene-targeted therapy (Intl J Oncol 36:1341-1353, 2010), and whose cause of canonization is ongoing.